Global Innovative Contracting Factbooks
Shaping Strategy, Empowering Leaders
Strategic Insights for Advancing Pharmaceutical Market Access, Pricing and Contracting
Inspiring intelligence, trusted by leaders of the world’s largest pharmaceutical businesses
Verpora’s Innovative Contracting Factbooks bridge the gap between market access professionals and the rapidly evolving landscape of payer agreements and contracting strategy.
Each quarterly edition compiles critical analyses, payer commentary surrounding recent market and regional IC launches, and the latest trends in Innovative Contracting and Value-Based Agreements (VBAs) from around the globe.
Whether augmenting your existing knowledge base or serving as a primary reference, the factbooks illuminate a pathway for decision-makers with the intelligence needed to navigate the complexities of global market access and pricing.
Our latest edition captures a global snapshot of the current state of Innovative Contracting, including highlights on South American and European policy changes. It also delves into US market changes, the payer challenges shaping contracting strategy in the neurology market, and direct commentary from payers on recent innovative contracting successes for Haemophilia and Sickle Cell disease…
March 2024 Factbook Summary
Content Highlights
-
Delve into the complexities faced by payers in assessing the next generation of Alzheimer's medicines and uncover some of the tactics they may employ to overcome these hurdles. Gain insights into how innovative contracting approaches could reshape the conversation around access and affordability.
-
The outcome of the current Medicare Drug Price Negotiations and have the potential to impact the future landscape of contracting within the United States healthcare system. We analyze some of the scenarios that may drive manufacturers to think about innovative contracting.
-
In the USA, CMS has recently revealed more about their plans for a Cell & Gene Access Model including the use of outcomes-based arrangements. We explore the details of this plan and use global analogues as an indicator for the how these access models may impact the roll out of advanced therapies.
-
For the second time, a German payer has engaged in a innovative contract for the product Roctavian. Our payer team explores this important case study from Germany which sets more precedents in funding mechanisms for ultra high cost therapies. Discover the unique insights and lessons learned that can potentially impact healthcare policies across the globe.
-
The launch of BlueBird Bio's therapy Lyfgenia has arrived in the USA, and has seen a series of innovative contracts to manage uncertainties with both commercial and government payers. We analyse the contract terms, and what that might mean for other manufacturers seeking to launch rare disease therapies.
Arrange Access
$7,995
One-off purchase
- Enquire now to arrange:
- Personalized statement of work
- Factbook presentation to your team from a Verpora expert
- Discounted 12-month subscription, 4x Factbooks - $20,000
Format
22 pages. Read-only PDF & Powerpoint
Designed to deliver accurate and reliable information, we combine desk-based research with advanced market analysis techniques to leverage payer databases, press releases, and academic articles to gather data on global innovative contracts. We prioritise quality assurance through peer review and continuous validation with leading payer experts.
